

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10586416
	Filing Date		2008-06-28
	First Named Inventor	CRUTCHER, Keith Alan	
	Art Unit	1654	
	Examiner Name	LUKTON, David	
	Attorney Docket Number	81599-004US0	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	7691382		2010-04-06	Dobson	
	2	8017579	B2	2011-09-13	Dobson	
If you wish to add additional U.S. Patent citation information please click the Add button.						Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020164789		2002-11-07	Laskowitz et al.	
	2	20070117746		2007-05-24	Dobson	
	3	20090048171		2009-02-19	Dobson	
	4	20100221273		2010-09-02	Dobson	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10586416
Filing Date	2008-08-28
First Named Inventor	CRUTCHER, Keith Alan
Art Unit	1654
Examiner Name	LUKTON, David
Attorney Docket Number	81599-004US0

5	20050208078		2005-09-22	Hoffman et al.	
6	20050266017		2005-12-01	Drulhe et al.	
7	20080207508		2008-08-28	Dobson	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

**FOREIGN PATENT DOCUMENTS**

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	2002015923	WO		2002-02-28	University of California		<input type="checkbox"/>
	2	19980042751	WO		1998-10-01	University of Leicester		<input type="checkbox"/>
	3	2003026479	WO		2003-04-03	Cognosol Inc.		<input type="checkbox"/>
	4	2005039534	WO		2005-05-06	Childrens Hospital		<input type="checkbox"/>
	5	2007000584	WO		2007-01-04	Ai2 Limited		<input type="checkbox"/>
	6	2003052076	WO		2003-06-26	Zamudio et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10586416
Filing Date	2008-08-28
First Named Inventor	CRUTCHER, Keith Alan
Art Unit	1654
Examiner Name	LUKTON, David
Attorney Docket Number	81599-004US0

7	2005082399	WO		2005-09-09	University of Manchester	<input type="checkbox"/>
8	1994004177	WO		1994-03-03	Rogosin Inst.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

**NON-PATENT LITERATURE DOCUMENTS**

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	CLAY, et al. "Localization of a Domain in Apolipoprotein E with both cytostatic and cytotoxic activity," Biochemistry, 1995;34: 11142-11151.	<input type="checkbox"/>
	2	GAIT, et al. "Progress in anti-HIV structure-based drug design," TIBTECH, October 1995: Vol. 13, 430-438.	<input type="checkbox"/>
	3	OLSSON, et al. "Possible functional interactions of Apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor," Arterioscler. Thromb. Vasc. Biol. 1997: 17, 149-155.	<input type="checkbox"/>
	4	HIRSCH, et al. "Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management," JAMA 1998: 279 (24); 1984-1991.	<input type="checkbox"/>
	5	WANG, et al. "Apolipoprotein E (ApoE) peptide regulates tau phosphorylation via two different signaling pathways," J. Neurosci Res. 1998: 51; 658-665.	<input type="checkbox"/>
	6	US 10/580,761 Office Action dated 1-9-2008 (Atty Dkt 81599-001US0)	<input type="checkbox"/>
	7	US 10/580,761 Office Action dated 6-24-2008 (Atty Dkt 81599-001US0)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10586416
Filing Date	2008-08-28
First Named Inventor	CRUTCHER, Keith Alan
Art Unit	1654
Examiner Name	LUKTON, David
Attorney Docket Number	81599-004US0

8	US 10/580,761 Office Action dated 11-26-2008 (Atty Dkt 81599-001US0)	<input type="checkbox"/>
9	US 10/580,761 Office Action dated 6-9-2009 (Atty Dkt 81599-001US0)	<input type="checkbox"/>
10	US 10/580,761 Notice of Allowance dated 11-2-2009 (Atty Dkt 81599-001US0)	<input type="checkbox"/>
11	US 10/580,984 Office Action dated 6-25-2009 (Atty Dkt 81599-002US0)	<input type="checkbox"/>
12	US 10/580,984 Office Action dated 12-22-2009 (Atty Dkt 81599-002US0)	<input type="checkbox"/>
13	US 10/580,984 Office Action dated 6-30-2010 (Atty Dkt 81599-002US0)	<input type="checkbox"/>
14	US 10/580,984 Office Action dated 12-3-2010 (Atty Dkt 81599-002US0)	<input type="checkbox"/>
15	OWENS, et al. "Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation," J. Clin. Invest., October 1990; Vol. 86; 1142-1150.	<input type="checkbox"/>
16	PCT/GB04/05360 ISR dated 10-4-2005 (001US0)	<input type="checkbox"/>
17	PCT/GB04/05360 Written Opinion dated 10-4-2005 (001US0)	<input type="checkbox"/>
18	PCT/GB04/05360 IPRP dated 6-20-2006 (001US0)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10586416
Filing Date	2008-08-28
First Named Inventor	CRUTCHER, Keith Alan
Art Unit	1654
Examiner Name	LUKTON, David
Attorney Docket Number	81599-004US0

19	PCT/GB04/05438 ISR dated 10-4-2005 (002US0)	<input type="checkbox"/>
20	PCT/GB04/05438 Written Opinion dated 10-4-2005 (002US0)	<input type="checkbox"/>
21	PCT/GB04/05438 IPRP dated 6-26-2006 (002US0)	<input type="checkbox"/>
22	PCT/GB06/02350 ISR dated 12-1-2006 (003US0)	<input type="checkbox"/>
23	PCT/GB06/02350 Written Opinion dated 12-1-2006 (003US0)	<input type="checkbox"/>
24	PCT/GB06/02350 IPRP dated 1-9-2008 (003US0)	<input type="checkbox"/>
25	PCT/GB05/00769 ISR dated 10-18-2005 (004US0)	<input type="checkbox"/>
26	PCT/GB05/00769 Written Opinion dated 10-18-2005 (004US0)	<input type="checkbox"/>
27	PCT/GB05/00769 IPRP dated 8-30-2006 (004US0)	<input type="checkbox"/>
28	US 11/916,627 Office Action dated 12-24-2009 (Atty Dkt. 81599-003US0)	<input type="checkbox"/>
29	US 11/916,627 Office Action dated 5-10-2010 (Atty Dkt. 81599-003US0)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10586416
Filing Date	2008-06-28
First Named Inventor	CRUTCHER, Keith Alan
Art Unit	1654
Examiner Name	LUKTON, David
Attorney Docket Number	81599-004US0

30	US 11/916,627 Office Action dated 12-15-2010 (Atty Dkt. 81599-003US0)	<input type="checkbox"/>
31	SRINIVAS, et al. "Inhibition of virus-induced cell fusion by Apolipoprotein A-I and its amphipathic peptide analogs," J. Cellular Biochemistry, 1991: Vol. 45; 224-237.	<input type="checkbox"/>
32	US 11/916,627 Non Final Office Action dated September 27, 2011 (Atty Ref: 81599-003US0)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10586416
Filing Date	2008-06-28
First Named Inventor	CRUTCHER, Keith Alan
Art Unit	1654
Examiner Name	LUKTON, David
Attorney Docket Number	81599-004US0

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Linda B. Truong/	Date (YYYY-MM-DD)	2011-10-11
Name/Print	Linda B. Truong	Registration Number	56461

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.